mRNA Technology Enters Cancer Treatment Era: Moderna's Breakthrough Sparks Surge in Chinese Biotech Leaders

Moderna (MRNA-US) and Merck (MRK-US) announced on Wednesday (19th) that their jointly developed personalized mRNA cancer vaccine, Intismeran, achieved historic success in a large-scale Phase III clinical trial, significantly reducing the risk of recurrence and distant spread in melanoma patients. Fueled by this landmark news, Moderna's stock price skyrocketed nearly 177% overnight. This momentum quickly swept across China's capital markets, sparking a full-scale breakout in the A-share pharmaceutical and biotechnology sectors.

At the opening of trading in mainland China, as many as 26 individual stocks in the sector surged to their daily 20% trading limits, signaling mRNA technology's official entry into the trillion-yuan era of tumor treatment.

For years, cancer vaccines have faced market skepticism over their druggability and technological feasibility due to a lack of large-scale clinical validation, resulting in suppressed valuations for related companies. This breakthrough success by Moderna marks the first time mRNA's viability in oncology has been validated through large-scale clinical trials, completely dismantling industry-wide cognitive barriers.

Stimulated by this major positive catalyst, leading Chinese vaccine and mRNA technology platform companies saw explosive gains in their share prices. CanSinoBIO (06185-HK), Walvax Biotech (300142-CN), and Zhifei Biological (300122-CN) all surged to 20% daily limits. Notably, Walvax Biotech benefits from extensive industrialization and technical experience gained through its approved emergency-use mRNA COVID-19 vaccine. CanSinoBIO, possessing multiple nucleic acid vaccine platforms, has seen its platform valuation significantly restructured. Meanwhile, vaccine leader Zhifei Biological may enter the mRNA cancer vaccine race through引进 partnerships.

Additionally, Abogen Biosciences, which focuses on core mRNA technologies and solid tumor vaccines, has had its prior R&D investments and GMP-compliant commercial production facilities revalued and affirmed by capital markets.

Beyond end-stage research and manufacturing, the rapid expansion of the global mRNA drug pipeline is directly boosting the prospects and stock prices of upstream Chinese suppliers of critical materials and bio-reagents. In this segment, Novozymes (Novegene) hit a 20% limit-up, and core supply chain players like GenScript were strongly driven upward.